ADVERTISEMENT

CROI 2022 — COVID-19 pneumonia: enpatoran delivers on safety but fails to meet efficacy endpoint

Pavankumar Kamat   |   Conference Report   |   16 February 2022
ADVERTISEMENT

Takeaway

  • Enpatoran failed to reduce time to recovery in patients hospitalized with acute COVID-19 pneumonia, but it was safe and well-tolerated.

Why this matters

  • Enpatoran is an investigational highly selective inhibitor of TLR7 and TLR8, which may potentially prevent a hyperinflammatory state and cytokine storm in patients with COVID-19 pneumonia....

          

September Challenge

Ends in 5d 17h
left
right

Topic Challenges

left
right